Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization
Advanced Science · 2025-07 · 12 (25)
DOI: 10.1002/advs.202414587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.04.2025. Verfasst von Chen Xuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Diabetic Nephropathies, Quercetin. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
At the convergence point of multiple cytokine signals, signal transducer and activator of transcription 3 (STAT3) is a highly promising therapeutic target for diabetic nephropathy. Isoquercitrin, a natural small‐molecule inhibitor of STAT3, may have beneficial effects on diabetic nephropathy; however, the underlying mechanism remains unclear. Isoquercitrin significantly mitigated renal inflammation and fibrosis by inhibiting STAT3 activity in mice with diabetic nephropathy. Moreover, STAT3 is a direct molecular target of isoquercitrin, which as corroborated by tight and stable noncovalent binding between them. This interaction is mechanistically supported by the affinity of isoquercitrin for the Ser668–Gln635–Gln633 region within the pY+1 binding pocket of the SH2 domain. This binding obstructs pivotal processes like STAT3 phosphorylation and dimerization, thereby suppressing its transcriptional function. Finally, a kidney‐targeted nanocarrier, Iso@PEG‐GK, is developed to load isoquercitrin, thus enhancing its therapeutic precision for diabetic nephropathy. Iso@PEG‐GK significantly improved the absorption and renal distribution of isoquercitrin. This study is the first to demonstrate that isoquercitrin exerts a significant protective effect against diabetic nephropathy and may provide a novel therapeutic drug for this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices a…
- School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Xuan, C., Chen, D., Zhang, S., Li, C., Fang, Q., Chen, D., Liu, J., Jiang, X., Zhang, Y., Shen, W., Cai, G., Chen, X., & Li, P. (2025). Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization. Advanced Science, 12(25). https://doi.org/10.1002/advs.202414587
Vancouver
Xuan C, Chen D, Zhang S, Li C, Fang Q, Chen D, et al. Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization. Advanced Science. 2025;12(25). doi:10.1002/advs.202414587
BibTeX
@article{Xuan2025,
author = {Xuan, Chen and Chen, Donghui and Zhang, Shuangna and Li, Chaofan and Fang, Qingyun and Chen, Dinghua and Liu, Jiabao and Jiang, Xin and Zhang, Yingjie and Shen, Wanjun and Cai, Guangyan and Chen, Xiangmei and Li, Ping},
title = {Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {25},
doi = {10.1002/advs.202414587}
}
EUVIMED